GoodRx Holdings Analysts Downgrade Price Target, Signals Caution

GoodRx Holdings faces downgrades from analysts with an average price target dropping to $6.25. Caution prevails as revenue growth shows slight improvement but sentiment shifts suggest potential volatility in stock performance.

Date: 09-01-2025

AI Rating: 5

Overview of Analyst Sentiments

The recent evaluation of GoodRx Holdings by analysts indicates a mixed outlook, with bullish sentiments overshadowed by recent downgrades in ratings and price targets. This shift is critical for investors to consider, as it reflects the changing dynamics within the healthcare sector.

Analyst Ratings Breakdown

In the last three months, GoodRx saw varying analyst ratings shifting from previous months. Currently, the ratings consist of:

1 Bullish, 2 Somewhat Bullish, 1 Indifferent

In the past 30 days, there has been a notable increase in bearish sentiment with no analysts rating the stock as bullish in this shorter timeframe compared to previous evaluations.

Price Target Adjustments

Analysts have adjusted their 12-month price targets, notably the average has fallen from $8.50 to $6.25, indicating a 26.47% decrease. Such adjustments highlight significant concern surrounding GoodRx's market performance and future valuations.

Specific price target changes include:

Scott Schoenhaus from Keybanc lowered the target from $7.00 to $6.00, rating it as Overweight.
Craig Hettenbach from Morgan Stanley also reduced the target to $6.00, maintaining an Equal-Weight rating.
Daniel Grosslight from Citigroup decreased the target dramatically from $10.00 to $7.00, retaining a Buy rating.
Stephanie Davis from Barclays lowered their target from $10.00 to $6.00, with an Overweight rating.

Financial Performance Metrics

Despite the changes in sentiment, GoodRx Holdings exhibited positive revenue growth, showing a solid growth rate of approximately 8.5% in the last three months. This growth surpasses sector averages, suggesting potential resilience in their top-line performance despite analyst downgrades.

Additionally, the company maintains a net margin of 2.03%, which exceeds industry averages, showcasing effective cost control and profitability even amidst market adjustments.

Return on Equity (ROE) stands at an impressive 0.58%, signaling effective management of equity capital and strong financial health. This highlights the company's potential for continued growth despite fluctuating analyst opinions.

In conclusion, while GoodRx Holdings is experiencing analyst downgrades and adjustment of price targets, its underlying financial performance metrics like revenue growth and profitability should not be overlooked as they may support stock resilience in challenging market conditions.

Stocks: GDRX